Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for NTLA

Stock NameIntellia Therapeutics Inc
TickerNTLA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45826J1051
LEI5493002T5BCPE5DZC723

Show aggregate NTLA holdings

News associated with NTLA

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach. - 2025-09-02 10:03:00
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up After Insider Buying Activity
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) shares gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $10.52, but opened at $11.07. Intellia Therapeutics shares last traded at $11.34, with a volume of 1,615,773 shares trading hands. Specifically, Director William J. Chase purchased 100,000 shares […] - 2025-08-27 02:18:42
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 24.1% in the 1st quarter, HoldingsChannel reports. The firm owned 21,458 shares of the company’s stock after buying an additional 4,165 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Intellia Therapeutics were worth […] - 2025-08-15 05:44:58
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty. - 2025-08-11 08:43:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by XTX Topco Ltd
XTX Topco Ltd boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 84.2% in the 1st quarter, HoldingsChannel reports. The firm owned 80,897 shares of the company’s stock after purchasing an additional 36,989 shares during the period. XTX Topco Ltd’s holdings in Intellia Therapeutics were worth $575,000 at the end of the […] - 2025-08-07 04:58:54
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks. - 2025-07-28 09:41:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating […] - 2025-07-24 05:11:08
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options
Investors considering a purchase of Intellia Therapeutics Inc (Symbol: NTLA) stock, but tentative about paying the going market price of $13.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in - 2025-07-21 12:36:47
Alps Advisors Inc. Sells 5,030 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Alps Advisors Inc. trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.1% in the 1st quarter, Holdings Channel reports. The firm owned 77,328 shares of the company’s stock after selling 5,030 shares during the quarter. Alps Advisors Inc.’s holdings in Intellia Therapeutics were worth $550,000 at the end of […] - 2025-07-15 06:25:51
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears. - 2025-07-14 10:06:00
Wealth Enhancement Advisory Services LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Wealth Enhancement Advisory Services LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,789 shares of the company’s stock, valued at approximately $98,000. Several other large investors also recently modified […] - 2025-07-11 04:16:51
Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $33.37
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given […] - 2025-07-02 03:14:50
SG Americas Securities LLC Sells 3,401 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
SG Americas Securities LLC lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,437 shares of the company’s stock after selling 3,401 shares during the quarter. SG Americas Securities LLC’s […] - 2025-06-27 04:21:01
Rhumbline Advisers Reduces Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Rhumbline Advisers trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 156,838 shares of the company’s stock after selling 9,410 shares during the quarter. Rhumbline Advisers’ holdings in […] - 2025-06-20 04:22:49
GAMMA Investing LLC Raises Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
GAMMA Investing LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1,961.2% during the first quarter, Holdings Channel.com reports. The firm owned 7,544 shares of the company’s stock after acquiring an additional 7,178 shares during the quarter. GAMMA Investing LLC’s holdings in Intellia Therapeutics were worth $540,000 at the end of […] - 2025-06-19 04:08:57
Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 213.15% from the company’s current […] - 2025-06-18 02:22:53
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one […] - 2025-06-04 04:52:47
Nuveen Asset Management LLC Sells 105,170 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Nuveen Asset Management LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 28.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 260,697 shares of the company’s stock after selling 105,170 shares during the quarter. Nuveen Asset Management LLC’s […] - 2025-06-03 06:04:57
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 483,185 shares of the company’s […] - 2025-06-03 05:13:02
ProShare Advisors LLC Has $389,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
ProShare Advisors LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 38.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 33,404 shares of the company’s stock after acquiring an additional 9,196 shares during the period. ProShare Advisors LLC’s holdings in Intellia Therapeutics were worth $389,000 at the end […] - 2025-05-29 05:04:57
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 15,888 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 227,255 shares of the company’s stock after buying an additional 15,888 shares during the period. MIRAE […] - 2025-05-21 05:40:53
BNP Paribas Financial Markets Has $5.11 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
BNP Paribas Financial Markets increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 78.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 438,458 shares of the company’s stock after purchasing an additional 192,096 shares during […] - 2025-05-14 06:12:50
Guggenheim Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target cut by investment analysts at Guggenheim from $55.00 to $45.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 440.87% from the stock’s previous close. […] - 2025-05-14 02:56:48
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $36.47 Consensus Target Price from Brokerages
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, thirteen have assigned a buy recommendation […] - 2025-05-13 02:44:49
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Cut by Voya Investment Management LLC
Voya Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,829 shares of the company’s stock after selling 2,213 shares during the period. Voya Investment Management LLC’s holdings in Intellia […] - 2025-05-12 05:26:58
Citigroup Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $10.00
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by Citigroup from $14.00 to $10.00 in a research note released on Friday,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities analysts have also commented on the stock. Wedbush restated a “neutral” rating and issued a $10.00 […] - 2025-05-12 04:26:47
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Mariner LLC
Mariner LLC decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 14.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,820 shares of the company’s stock after selling 2,496 shares during the quarter. Mariner LLC’s holdings in Intellia Therapeutics were worth […] - 2025-05-08 04:38:44
Dimensional Fund Advisors LP Purchases 528,962 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Dimensional Fund Advisors LP increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 36.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,976,212 shares of the company’s stock after purchasing an additional 528,962 shares during the quarter. […] - 2025-05-07 05:26:54
MetLife Investment Management LLC Buys 3,491 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
MetLife Investment Management LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,187 shares of the company’s stock after purchasing an additional 3,491 shares during the period. […] - 2025-05-05 05:22:56
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again. Her most popular exchange-traded fund has risen 6% over the past month, a welcome contrast to the flat overall market in that time. Her 14% retur - 2025-04-30 11:15:00

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) NTLA holdings

DateNumber of NTLA Shares HeldBase Market Value of NTLA SharesLocal Market Value of NTLA SharesChange in NTLA Shares HeldChange in NTLA Base ValueCurrent Price per NTLA Share HeldPrevious Price per NTLA Share Held
2025-11-11 (Tuesday)69,778USD 710,340NTLA holding increased by 31400USD 710,3400USD 31,400 USD 10.18 USD 9.73
2025-11-10 (Monday)69,778NTLA holding increased by 180USD 678,940NTLA holding increased by 16367USD 678,940180USD 16,367 USD 9.73 USD 9.52
2025-11-07 (Friday)69,598USD 662,573NTLA holding decreased by -194874USD 662,5730USD -194,874 USD 9.52 USD 12.32
2025-11-06 (Thursday)69,598NTLA holding increased by 179USD 857,447NTLA holding decreased by -84569USD 857,447179USD -84,569 USD 12.32 USD 13.57
2025-11-05 (Wednesday)69,419USD 942,016NTLA holding increased by 95104USD 942,0160USD 95,104 USD 13.57 USD 12.2
2025-11-04 (Tuesday)69,419NTLA holding increased by 180USD 846,912NTLA holding decreased by -58042USD 846,912180USD -58,042 USD 12.2 USD 13.07
2025-11-03 (Monday)69,239USD 904,954NTLA holding increased by 31158USD 904,9540USD 31,158 USD 13.07 USD 12.62
2025-10-31 (Friday)69,239USD 873,796NTLA holding increased by 24580USD 873,7960USD 24,580 USD 12.62 USD 12.265
2025-10-30 (Thursday)69,239NTLA holding increased by 900USD 849,216NTLA holding decreased by -47392USD 849,216900USD -47,392 USD 12.265 USD 13.12
2025-10-29 (Wednesday)68,339NTLA holding increased by 360USD 896,608NTLA holding decreased by -52379USD 896,608360USD -52,379 USD 13.12 USD 13.96
2025-10-28 (Tuesday)67,979USD 948,987NTLA holding decreased by -56422USD 948,9870USD -56,422 USD 13.96 USD 14.79
2025-10-27 (Monday)67,979USD 1,005,409NTLA holding decreased by -734853USD 1,005,4090USD -734,853 USD 14.79 USD 25.6
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NTLA by Blackrock for IE00BYXG2H39

Show aggregate share trades of NTLA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY18010.7709.650 9.762USD 1,757 11.76
2025-11-06BUY17913.50012.220 12.348USD 2,210 11.77
2025-11-04BUY18013.11012.190 12.282USD 2,211 11.76
2025-10-30BUY90012.70011.630 11.737USD 10,563 11.75
2025-10-29BUY36013.12014.000 13.912USD 5,008 11.74
2025-10-22SELL-71624.58026.900 26.668USD -19,094 11.49 Loss of -10,867 on sale
2025-10-20BUY35827.98028.250 28.223USD 10,104 11.32
2025-10-17BUY89424.75025.180 25.137USD 22,472 11.24
2025-10-15BUY1,42425.93026.319 26.280USD 37,423 11.16
2025-10-03BUY1,26019.96020.980 20.878USD 26,306 11.04
2025-10-02BUY18020.44020.585 20.570USD 3,703 10.99
2025-09-30BUY36017.27017.530 17.504USD 6,301 10.91
2025-09-26BUY36016.31016.619 16.588USD 5,972 10.84
2025-09-25BUY36016.61017.470 17.384USD 6,258 10.81
2025-09-24BUY18217.76018.575 18.494USD 3,366 10.77
2025-09-17BUY54312.41013.100 13.031USD 7,076 10.73
2025-08-20SELL-72010.21010.350 10.336USD -7,442 10.72 Profit of 277 on sale
2025-07-30BUY71612.33013.070 12.996USD 9,305 10.70
2025-07-17SELL-35811.83012.400 12.343USD -4,419 10.57 Loss of -634 on sale
2025-07-11SELL-1,44011.53512.125 12.066USD -17,375 10.54 Loss of -2,197 on sale
2025-07-07BUY54010.25010.825 10.767USD 5,814 10.52
2025-07-02BUY9,90010.73011.080 11.045USD 109,345 10.51
2025-06-20BUY2,7639.2009.943 9.869USD 27,267 10.52
2025-06-11BUY3448.3708.688 8.656USD 2,978 10.60
2025-06-10BUY3468.4709.125 9.060USD 3,135 10.62
2025-06-04SELL-1737.6707.840 7.823USD -1,353 10.71 Profit of 499 on sale
2025-04-23BUY1728.0908.900 8.819USD 1,517 11.41
2025-04-10SELL-1,3766.7706.910 6.896USD -9,489 11.81 Profit of 6,768 on sale
2025-04-08SELL-1726.2807.030 6.955USD -1,196 11.93 Profit of 856 on sale
2025-04-07SELL-1726.5406.880 6.846USD -1,178 12.00 Profit of 886 on sale
2025-04-04SELL-8656.6306.910 6.882USD -5,953 12.06 Profit of 4,477 on sale
2025-04-01BUY7086.6557.135 7.087USD 5,018 12.18
2025-03-31SELL-5197.1107.830 7.758USD -4,026 12.24 Profit of 2,327 on sale
2025-03-21BUY3,0429.0009.075 9.067USD 27,583 12.53
2025-03-14SELL-2,6249.1409.600 9.554USD -25,070 12.76 Profit of 8,420 on sale
2025-03-07SELL-32610.35010.680 10.647USD -3,471 13.00 Profit of 768 on sale
2025-03-04SELL-1639.0959.530 9.486USD -1,546 13.17 Profit of 601 on sale
2025-02-25BUY32610.71011.860 11.745USD 3,829 13.41
2025-02-19SELL-16212.28012.800 12.748USD -2,065 13.51 Profit of 124 on sale
2025-02-13BUY4869.6409.715 9.708USD 4,718 13.74
2025-02-12BUY1629.5109.580 9.573USD 1,551 13.83
2025-02-11BUY6489.2109.476 9.449USD 6,123 13.93
2024-12-30SELL-5,49311.41011.850 11.806USD -64,850 15.51 Profit of 20,349 on sale
2024-11-18SELL-2,62514.17015.200 15.097USD -39,630 16.51 Profit of 3,714 on sale
2024-11-08SELL-17516.73016.995 16.969USD -2,969 16.49 Loss of -84 on sale
2024-10-21SELL-17520.67021.093 21.051USD -3,684 0.00 Loss of -3,684 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NTLA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-192,488,21625,9124,783,02652.0%
2025-09-183,275,17025,8088,092,76240.5%
2025-09-171,795,7605,8053,049,64858.9%
2025-09-16882,7801,1103,448,05925.6%
2025-09-15742,270871,788,36241.5%
2025-09-12722,3354001,382,22152.3%
2025-09-11875,8647,0541,871,68146.8%
2025-09-101,504,2395,7622,264,60066.4%
2025-09-091,403,87413,3412,383,47558.9%
2025-09-08918,1171381,520,95960.4%
2025-09-051,009,1372,1442,403,55642.0%
2025-09-04673,3557,2371,306,22151.5%
2025-09-031,086,3501,5832,619,35341.5%
2025-09-02670,3971,1671,423,04747.1%
2025-08-29537,4682,1001,149,46646.8%
2025-08-28861,12701,850,84046.5%
2025-08-27562,88531,151,55148.9%
2025-08-26587,4712181,339,28243.9%
2025-08-25944,6762,5342,848,39633.2%
2025-08-22471,9941,0101,271,51237.1%
2025-08-21664,42001,098,36860.5%
2025-08-20717,6611751,330,49753.9%
2025-08-191,307,3613,2091,995,17365.5%
2025-08-18749,6934,8521,667,25045.0%
2025-08-15929,7746292,294,40440.5%
2025-08-141,573,7209482,631,09059.8%
2025-08-131,587,3051,2572,999,67352.9%
2025-08-12943,0332,9121,526,98161.8%
2025-08-11673,8925961,352,23349.8%
2025-08-081,135,0265,9191,684,23567.4%
2025-08-07930,5373051,823,81751.0%
2025-08-06841,9404551,751,62648.1%
2025-08-05766,4981531,479,64951.8%
2025-08-04806,2139811,511,50753.3%
2025-08-011,211,5522,1212,016,62260.1%
2025-07-311,494,6036,2362,951,39850.6%
2025-07-30876,6011,3001,994,39444.0%
2025-07-29903,3802,8932,182,94441.4%
2025-07-28602,1541,7131,783,81433.8%
2025-07-25830,629114,1572,043,99840.6%
2025-07-241,624,048106,0133,581,47745.3%
2025-07-231,590,06513,5703,054,68352.1%
2025-07-22899,4603,2991,834,33049.0%
2025-07-211,344,5376,3712,694,80349.9%
2025-07-18725,1296321,386,25452.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.